Joint Ministry Initiative Seeks Evidence-Based Guidelines for Gender Dysphoria in Minors with Triptorelin Use

Schillaci and Roccella Collaborating on New guidelines for Triptorelin Dysphoria

In a bid to address the complex issue of gender dysphoria in minors, the Ministry of Health and the Ministry of Family have initiated a joint discussion on the use of triptorelin, a puberty blocking drug. The initiative is being led by Ministers Orazio Schillaci and Eugenia Roccella, with a team of technicians and experts set to develop new guidelines based on a review of scientific literature and experiences from other countries that are reevaluating their positions after widespread use of these drugs.

The two ministries released a joint statement announcing this initiative and summarizing the work done so far on gender dysphoria and the use of blockers. The statement mentions that the initiative follows a hearing with scientific societies involved in the issue of gender dysphoria in adolescents and a request made to the National Bioethics Committee to reevaluate the use of triptorelin in cases of gender dysphoria in minors. The ministries are also conducting a survey among regions regarding clinical monitoring, expenditures, and prescriptions of triptorelin for cases of dysphoria, and have requested a report from AIFA on the therapeutic indications for the drug.

This collaborative effort represents a proactive approach to addressing the complex issue of gender dysphoria in minors, with a focus on evidence-based guidelines and best practices. Stay tuned for updates as the table

Leave a Reply